These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32289176)

  • 21. Treatment of Guillain-Barré syndrome: a review.
    Rajabally YA
    Inflamm Allergy Drug Targets; 2012 Aug; 11(4):330-4. PubMed ID: 22452606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guillain-Barré Syndrome and Posterior Reversible Encephalopathy Syndrome following Spinal Surgery.
    Sanpei Y; Hanazono A; Kamada S; Sugawara M
    Case Rep Neurol; 2019; 11(3):284-289. PubMed ID: 31607895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [PRES: Posterior Reversible Encephalopathy Syndrome].
    Okamoto K; Motohashi K; Fujiwara H; Ishihara T; Ninomiya I; Onodera O; Fujii Y
    Brain Nerve; 2017 Feb; 69(2):129-141. PubMed ID: 28202821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Posterior reversible encephalopathy syndrome associated with IVIG in a patient with Guillain-Barré syndrome.
    Koichihara R; Hamano S; Yamashita S; Tanaka M
    Pediatr Neurol; 2008 Aug; 39(2):123-5. PubMed ID: 18639758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Posterior reversible encephalopathy syndrome as the initial manifestation of Guillain-Barré syndrome: case report and review of the literature.
    Rigamonti A; Basso F; Scaccabarozzi C; Lauria G
    J Peripher Nerv Syst; 2012 Sep; 17(3):356-60. PubMed ID: 22971098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action.
    Shahrizaila N; Yuki N
    Expert Opin Pharmacother; 2011 Jul; 12(10):1551-60. PubMed ID: 21473704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous immunoglobulin vs plasma exchange in treatment of mechanically ventilated adults with Guillain-Barré syndrome.
    Charra B; Hachimi A; Benslama A; Motaouakkil S
    Pan Afr Med J; 2014; 18():35. PubMed ID: 25368724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Acute encephalopathy associated with the use of intravenous immunoglobulin. Report of one case].
    Soto V A; Cartier R L
    Rev Med Chil; 2011 Oct; 139(10):1340-3. PubMed ID: 22286735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. One thing leads to another: GBS complicated by PRES and Takotsubo cardiomyopathy.
    Fugate JE; Wijdicks EF; Kumar G; Rabinstein AA
    Neurocrit Care; 2009 Dec; 11(3):395-7. PubMed ID: 19813106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Novel Therapeutic Interventions in Guillain-Barré Syndrome: Review and Future Perspective].
    Misawa S
    Brain Nerve; 2015 Nov; 67(11):1421-8. PubMed ID: 26560957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Posterior reversible encephalopathy syndrome as a complication of Guillain-Barré syndrome.
    Bavikatte G; Gaber T; Eshiett MU
    J Clin Neurosci; 2010 Jul; 17(7):924-6. PubMed ID: 20409715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversible cerebral vasoconstriction syndrome in Guillain-Barre syndrome: a case report and literature review.
    Seok HY; Eun MY; Kim S; Lee JJ; Oh GR; Kim GY; Sohn SI
    Neurol Sci; 2024 Jan; 45(1):101-107. PubMed ID: 37676373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guillain Barré syndrome-related posterior reversible encephalopathy syndrome.
    Zuccoli G; Nardone R; Hoda AH
    Neuroradiology; 2015 Jul; 57(7):755-6. PubMed ID: 25652259
    [No Abstract]   [Full Text] [Related]  

  • 34. Headache in Guillain-Barré Syndrome: Diagnostic and Management Implications.
    Alrohimi A; Jassal R
    Can J Neurol Sci; 2018 Mar; 45(2):240-242. PubMed ID: 29506598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional outcomes following inpatient rehabilitation of Guillain-Barré syndrome patients: Intravenous immunoglobulins versus plasma exchange.
    Bondi M; Engel-Haber E; Wolff J; Grosman-Rimon L; Bloch A; Zeilig G
    NeuroRehabilitation; 2021; 48(4):543-551. PubMed ID: 34024788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy of Guillain-Barré syndrome.
    Liu S; Dong C; Ubogu EE
    Hum Vaccin Immunother; 2018; 14(11):2568-2579. PubMed ID: 29953326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison on therapeutic effect of plasma exchange and intravenous immunoglobulin for Guillian-Barre syndrome.
    Ye Y; Li SL; Li YJ
    Transfus Med; 2015 Apr; 25(2):79-84. PubMed ID: 25515056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guillain-Barré syndrome: immunopathogenesis and therapeutic targets.
    Liu S; Zhang WW; Jia L; Zhang HL
    Expert Opin Ther Targets; 2024 Mar; 28(3):131-143. PubMed ID: 38470316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Posterior reversible encephalopathy syndrome and stroke after intravenous immunoglobulin treatment in Miller-Fisher syndrome/Bickerstaff brain stem encephalitis overlap syndrome.
    Stetefeld HR; Lehmann HC; Fink GR; Burghaus L
    J Stroke Cerebrovasc Dis; 2014 Oct; 23(9):e423-5. PubMed ID: 25149206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Efficacy of Intravenous Immunoglobulin in Guillain-Barré Syndrome: The Experience of a Tertiary Medical Center.
    Shalem D; Shemer A; Shovman O; Shoenfeld Y; Kivity S
    Isr Med Assoc J; 2018 Dec; 20(12):754-760. PubMed ID: 30550005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.